Landos Biopharma, Inc. (NASDAQ:LABP) Sees Significant Decrease in Short Interest

Landos Biopharma, Inc. (NASDAQ:LABPGet Free Report) was the target of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 14,700 shares, a drop of 10.9% from the October 15th total of 16,500 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average daily volume of 5,800 shares, the days-to-cover ratio is currently 2.5 days.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of LABP. BlackRock Inc. raised its stake in Landos Biopharma by 10.6% during the first quarter. BlackRock Inc. now owns 520,308 shares of the company’s stock worth $767,000 after purchasing an additional 49,880 shares during the period. Renaissance Technologies LLC raised its position in shares of Landos Biopharma by 99.0% in the 1st quarter. Renaissance Technologies LLC now owns 340,500 shares of the company’s stock worth $502,000 after buying an additional 169,400 shares during the period. Vanguard Group Inc. boosted its holdings in Landos Biopharma by 30.6% in the third quarter. Vanguard Group Inc. now owns 166,608 shares of the company’s stock valued at $108,000 after acquiring an additional 39,053 shares during the last quarter. Bank of America Corp DE increased its stake in Landos Biopharma by 80.4% during the first quarter. Bank of America Corp DE now owns 56,321 shares of the company’s stock worth $83,000 after acquiring an additional 25,096 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Landos Biopharma by 119.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 42,800 shares of the company’s stock worth $31,000 after purchasing an additional 23,263 shares during the period.

Landos Biopharma Stock Up 2.5 %

Shares of NASDAQ:LABP traded up $0.10 during midday trading on Friday, reaching $4.12. The company’s stock had a trading volume of 1,499 shares, compared to its average volume of 20,735. The firm has a market cap of $12.85 million, a price-to-earnings ratio of -1.09 and a beta of -0.71. The business has a 50 day moving average price of $3.79 and a 200 day moving average price of $3.86. Landos Biopharma has a 1 year low of $2.11 and a 1 year high of $6.20.

Landos Biopharma Company Profile

(Get Free Report)

Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract.

See Also

Receive News & Ratings for Landos Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landos Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.